Skin Cancer Model: J000106560

NSG™ mice engrafted with passage 8 tumors for model J000106560 were randomly assigned to one of these treatment groups:

• 0.5% carboxymethyl cellulose (CMC) (vehicle control; 10 ml/kg; PO daily for 21 days; N=10)
• Cisplatin (2 mg/kg; IV once per week for three times; N=10)
• Dabrafenib (100 mg/kg; PO daily for 21 days; N=10)
• Temozolomide (30 mg/kg; PO daily for 21 days; N=10)

Mice were monitored for tumor volume at least twice per week throughout the study period.

• Treatment groups     • Individual subjects / spider plot     • RECIST scores     • Waterfall plot     • TGI plot         • Protocols